Literature DB >> 1311237

Beta-endorphin inhibits hypoglycemia-induced gene expression of corticotropin-releasing factor in the rat hypothalamus.

T Suda1, Y Sato, T Sumitomo, Y Nakano, F Tozawa, I Iwai, M Yamada, H Demura.   

Abstract

Endogenous opioid peptides have a role in the regulation of the hypothalamic-pituitary-adrenal axis. Recently, beta-endorphin (EP) has been thought to inhibit CRF release in vivo and in vitro. In the present study we examined the effects of central administration of EP on ACTH secretion and gene expression of both CRF in the hypothalamus and POMC in the anterior pituitary gland (AP) during basal and insulin-induced hypoglycemia in pentobarbital-anesthetized rats. Administration of EP in the lateral ventricle decreased basal CRF levels in the median eminence and inhibited basal and hypoglycemia-induced ACTH secretion in a dose-dependent manner. Hypoglycemia-induced POMC mRNA levels in the AP and CRF mRNA levels in the hypothalamus were also dose-dependently inhibited by the administration of EP. The inhibitory effect of EP was reversed by naloxone. These results suggest that 1) central administration of EP acts through the opioid receptor to inhibit hypoglycemia-induced CRF gene expression in the hypothalamus and CRF release, which results in a decrease in ACTH secretion and POMC mRNA levels in the AP; and 2) the active site of EP is the CRF neuron in the paraventricular nucleus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311237     DOI: 10.1210/endo.130.3.1311237

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Evaluation of the counter-regulatory responses to hypoglycaemia in patients with type 1 diabetes during opiate receptor blockade with naltrexone.

Authors:  Sarita Naik; Renata Belfort-DeAguiar; Anne-Sophie Sejling; Barbara Szepietowska; Robert S Sherwin
Journal:  Diabetes Obes Metab       Date:  2017-02-17       Impact factor: 6.577

2.  Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus.

Authors:  Septimiu Vele; Sofiya Milman; Harry Shamoon; Ilan Gabriely
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

3.  Magnitude of exercise-induced β-endorphin response is associated with subsequent development of altered hypoglycemia counterregulation.

Authors:  Sofiya Milman; James Leu; Harry Shamoon; Septimiu Vele; Ilan Gabriely
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

4.  Opioid receptor blockade prevents exercise-associated autonomic failure in humans.

Authors:  Sofiya Milman; James Leu; Harry Shamoon; Septimiu Vele; Ilan Gabriely
Journal:  Diabetes       Date:  2012-04-20       Impact factor: 9.461

5.  Naloxone, but not valsartan, preserves responses to hypoglycemia after antecedent hypoglycemia: role of metabolic reprogramming in counterregulatory failure.

Authors:  Michal M Poplawski; Jason W Mastaitis; Charles V Mobbs
Journal:  Diabetes       Date:  2010-09-01       Impact factor: 9.461

6.  Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure.

Authors:  Eric Lontchi-Yimagou; Sandra Aleksic; Raphael Hulkower; Rebekah Gospin; Akankasha Goyal; Bryan Kuo; William G Mitchell; Jee Young You; Laxmi Upadhyay; Michelle Carey; Oana A Sandu; Ilan Gabriely; Harry Shamoon; Meredith Hawkins
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

7.  Opioid Receptor Activation Impairs Hypoglycemic Counterregulation in Humans.

Authors:  Michelle Carey; Rebekah Gospin; Akankasha Goyal; Nora Tomuta; Oana Sandu; Armand Mbanya; Eric Lontchi-Yimagou; Raphael Hulkower; Harry Shamoon; Ilan Gabriely; Meredith Hawkins
Journal:  Diabetes       Date:  2017-08-31       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.